VivoSeq
Other

Colitis

32

Pipeline Programs↗

12

Active Trials↗

15

Companies Involved↗

Colitis is a moderately active landscape with 32 programs across 15 companies. The most active players are AbbVie, Takeda, Bayer. 6 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

27/100

Mech. Concentration

29/100

Completion Rate

60/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 1Takeda logo

Takeda

2 programs

Phase 2Bayer logo

Bayer

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3Ferring logo

Ferring

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

30 of 36 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody411%Protein / enzyme13%Cell therapy13%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed12 · 32%
Recruiting9 · 24%
Unknown status5 · 14%
Withdrawn4 · 11%
Terminated4 · 11%
Not yet recruiting2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

37 trials

Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)
Recruiting·—·Phase 2·NCT06499896·30 enrolled
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
Recruiting·OOdense University Hospital·Phase 3·NCT05947669·195 enrolled
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
Recruiting·—·Phase 2·NCT02127398·77 enrolled
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05663775·20 enrolled
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis
Recruiting·—·Phase 2/3·NCT07047339·120 enrolled
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Recruiting·SShilpa Grover, MD, MPH·Phase 2·NCT06841705·80 enrolled
Study of Novel Therapeutics for Acute Remedy of Colitis
Recruiting·—·Phase 2·NCT06420492·20 enrolled
A Multi-Center, Non-Interventional Study on Effectiveness and Treatment Persistence of Guselkumab in Patients With ULcerative Colitis and Crohn's DiseasE in Real-World Practice in Saudi Arabia
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07541261·100 enrolled
Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides Difficile Infection 2: A Randomized Controlled Trial
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT07328971·500 enrolled
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04305145·42 enrolled
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
Not yet recruiting·MMedical College of Wisconsin·Phase 1·NCT06884748·30 enrolled
Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Not yet recruiting·—·N/A·NCT06874673·438 enrolled
Predicting Response to Standardized Pediatric Colitis Therapy
Completed·—·Phase 4·NCT01536535·431 enrolled
The Colitis Once Daily Asacol Study
Completed·—·Phase 3·NCT00708656·213 enrolled
Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa
Completed·MMedical University of Graz·N/A·NCT03460847·114 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)